Hymenoptera venom allergy ranks among the top three causes of anaphylaxis worldwide,
and approximately one‐quarter of sting‐induced reactions are classified as severe. Fatal …

Allergen-specific immunotherapy is the only curative treatment of honeybee venom (HBV)
allergy, which is able to protect against further anaphylactic sting reactions. Recent analyses …

Stings of Hymenoptera can induce IgE‐mediated systemic and even fatal allergic reactions.
Venom‐specific immunotherapy (VIT) is the only disease‐modifying and curative treatment …

Systemic allergic reactions to insect stings affect up to 5% of the population during their
lifetime, and up to 32% of beekeepers. Such reactions can be fatal, albeit very rarely, and …

Abstract Purpose of Review In Hymenoptera venom allergy, the research focus has moved
from whole venoms to individual allergenic molecules. Api m 10 (icarapin) has been …

Background The hypothetical risks of cardiovascular medication during Hymenoptera
venom immunotherapy (VIT) are still a matter of controversy. Objective To assess the …

Allergy to Polistes dominula (European paper wasp) venom is of particular relevance in
Southern Europe, potentially becoming a threat in other regions in the near future, and can …

The Honeybee (Apis mellifera) is one of the world's most beneficial insects, as it plays a
critical role in many terrestrial ecosystems. The use of honeybee products has been …

Venom immunotherapy (VIT) is the most effective form of specific immunotherapy to date.
Hitherto, several relevant queries remain unanswered, namely optimal doses, duration, and …

The prevalence of systemic reactions to hymenoptera stings is up to 7.5%. Venom-specific
immunotherapy (VIT) is an established treatment for insect venom allergy. In order to monitor …